uniQure N.V. (QURE) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-03-31..
Operating margin
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -191.74M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 1.71M USD | Cost of Goods and Services Sold |
| Research and development | 133.71M USD | Research and Development Expense |
| Selling, general and administration | 74.62M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $-191.74M | (m) | $1.71M | $133.71M | $74.62M | (m) |
| 2025-12-31 | $-185.35M | (m) | $1.69M | $140.67M | $65.46M | (m) |
| 2025-09-30 | $-180.06M | (m) | $1.87M | $144.73M | $55.22M | (m) |
| 2025-06-30 | $-169.25M | (m) | $1.74M | $140.96M | $47.36M | (m) |
| 2025-03-31 | $-169.40M | (m) | $1.31M | $139.23M | $49.63M | (m) |
| 2024-12-31 | $-184.29M | (m) | $1.27M | $143.78M | $52.66M | (m) |
| 2024-09-30 | $-200.21M | (m) | (m) | $147.56M | $58.77M | (m) |
| 2024-06-30 | $-241.86M | (m) | (m) | $182.37M | $65.27M | (m) |
| 2024-03-31 | $-262.93M | (m) | (m) | $194.75M | $70.68M | (m) |
| 2023-12-31 | $-282.87M | (m) | $65.00K | $214.86M | $74.59M | (m) |
| 2023-09-30 | $-194.62M | (m) | (m) | $230.57M | $75.36M | (m) |
| 2023-06-30 | $-172.26M | (m) | (m) | $213.24M | $70.61M | (m) |
| 2023-03-31 | $-163.25M | (m) | (m) | $213.40M | $61.92M | (m) |
| 2022-12-31 | $-143.16M | (m) | $1.25M | $197.59M | $55.06M | (m) |
| 2022-09-30 | $-167.59M | (m) | (m) | $181.60M | $50.77M | (m) |
| 2022-06-30 | $-153.07M | (m) | (m) | $169.97M | $49.47M | (m) |
| 2022-03-31 | $301.00M | (m) | (m) | $155.90M | $54.90M | (m) |
| 2021-12-31 | $310.62M | (m) | $24.98M | $143.55M | $56.29M | (m) |
| 2021-09-30 | $300.29M | (m) | (m) | $132.89M | $53.53M | (m) |
| 2021-06-30 | $300.80M | (m) | (m) | $132.76M | $52.30M | (m) |
| 2021-03-31 | $-135.42M | (m) | (m) | $129.04M | $45.88M | (m) |
| 2020-12-31 | $-125.43M | (m) | $2.90M | $122.40M | $42.58M | (m) |
| 2020-09-30 | $-150.14M | (m) | (m) | $117.21M | $40.05M | (m) |
| 2020-06-30 | $-136.98M | (m) | (m) | $104.46M | $38.19M | (m) |
| 2020-03-31 | $-128.10M | (m) | (m) | $100.21M | $34.55M | (m) |
| 2019-12-31 | $-121.14M | (m) | $1.65M | $94.74M | $33.54M | (m) |
| 2019-09-30 | $-112.37M | (m) | (m) | $86.96M | $32.08M | (m) |
| 2019-06-30 | $-104.27M | (m) | (m) | $83.95M | $29.05M | (m) |
| 2019-03-31 | $-96.14M | (m) | (m) | $78.29M | $27.07M | (m) |
| 2018-12-31 | $-88.23M | (m) | $1.20M | $74.81M | $25.30M | (m) |
| 2018-09-30 | $-86.67M | $12.26M | (m) | $74.30M | $25.38M | -706.94% |
| 2018-06-30 | $-72.72M | $11.37M | (m) | $73.86M | $25.06M | -639.48% |
| 2018-03-31 | $-71.23M | $13.26M | (m) | $72.24M | $24.58M | -536.99% |
| 2017-12-31 | $-71.34M | $13.11M | (m) | $72.17M | $24.64M | -544.31% |
| 2017-09-30 | $-65.09M | $19.65M | (m) | $73.94M | $23.11M | -331.18% |
| 2017-06-30 | $-69.98M | $24.61M | (m) | $70.44M | $22.64M | -284.28% |
| 2017-03-31 | $-72.40M | $24.12M | (m) | $72.80M | $25.06M | -300.10% |
| 2016-12-31 | $-71.95M | $25.10M | (m) | $72.51M | $26.00M | -286.66% |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-71.15M | $10.58M | (m) | $59.13M | $23.38M | -672.63% |
| 2014-12-31 | $-53.68M | $6.14M | (m) | $43.77M | $17.07M | -874.16% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |